ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2016
IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.
Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.American journal of respiratory and critical care medicine · 2021Trial
- Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEVJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2019Trial
- Predicting Pulmonary Exacerbations in Cystic Fibrosis Using Inflammation-Based Scoring Systems.Diagnostics (Basel, Switzerland) · 2025Article
- Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis.Pediatric pulmonology · 2025Article
- Diagnosis and Management of Cystic Fibrosis Exacerbations.Seminars in respiratory and critical care medicine · 2023Review
- The association of fecal calprotectin and respiratory exacerbation in cystic fibrosis patients.BMC gastroenterology · 2022Article
- Antipseudomonal treatment decisions during CF exacerbation management.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022Article
- A new path for CF clinical trials through the use of historical controls.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022Article
- Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021Article
- Observational
- Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.American journal of respiratory and critical care medicine · 2020Review
- Application of multiple event analysis as an alternative approach to studying pulmonary exacerbations as an outcome measure.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2020Observational
- The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2019Article
- Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis.Annals of the American Thoracic Society · 2019Article
- Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.Lancet (London, England) · 2018Review
- The expression of Mirc1/Mir17-92 cluster in sputum samples correlates with pulmonary exacerbations in cystic fibrosis patients.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2018Article
- Rescue therapy within the UK Cystic Fibrosis Registry: An exploration of predictors of intravenous antibiotic use amongst adults with CF.Respirology (Carlton, Vic.) · 2018Article
- Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations.F1000Research · 2018Review
- Antibiotic duration and changes in FEVBMC pulmonary medicine · 2017Article
- Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.Pediatric pulmonology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundSingle-center analyses have suggested that the number of CF pulmonary exacerbations (PEx) treated with intravenous antibiotics an individual has experienced in the prior year is significantly associated with their future PEx hazard.
methodsWe studied Prior-year PEx association with future PEx hazard by Cox proportional hazards regression among CF Foundation Patient Registry patients who experienced PEx after Jan 1, 2010.
resultsAmong 13,579 patients, those with 1, 2, 3, or ≥4 Prior-year PEx treated with intravenous antibiotics were at 1.8, 2.9, 4.8, and 8.7 higher PEx hazard vs those without (P<.0001). Adjustment with significant demographic and clinical covariates (univariate P≤.0001) reduced Prior-year PEx hazard ratios to 1.6, 2.4, 3.6, and 6.0 (P<.0001). No other covariates had adjusted hazard ratios of >1.7.
conclusionsPrior-year PEx strongly associate with future PEx hazard and should be accounted for in prospective trials where treatment-associated change in PEx hazard is an efficacy outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.